More joy for Lilly as dulaglutide gets EU go-ahead
This article was originally published in Scrip
Just a week after the US FDA approved Lilly's new antidiabetic, Trulicity (dulaglutide), the EU's CHMP has granted a positive opinion for its use in type 2 diabetes.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.